Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Alpha-Linolenic Acid (ALA) is an omega-3 polyunsaturated fatty acid found primarily in plant sources such as flaxseed, chia seeds, and walnuts. There is growing scientific interest in its potential role in supporting metabolic health, including in people with Metabolic Syndrome—a cluster of conditions encompassing central obesity, dyslipidemia, hypertension, and insulin resistance.

Several observational studies have suggested that higher dietary intake of ALA is associated with reduced risk of cardiovascular disease and improved lipid profiles, both key concerns in Metabolic Syndrome. Some small randomized controlled trials have indicated that ALA supplementation may modestly reduce triglyceride levels and blood pressure. For example, a meta-analysis published in Nutrition Reviews (2012) found minor but significant improvements in some metabolic parameters with ALA supplementation.

However, the evidence is mixed and generally weaker than that supporting marine-derived omega-3 fatty acids (EPA and DHA). The conversion of ALA to EPA and DHA in the human body is inefficient, which may limit its effectiveness. Large-scale, high-quality clinical trials specifically examining ALA’s impact on all components of Metabolic Syndrome are lacking.

In summary, while there is some scientific evidence supporting ALA’s use in addressing certain aspects of Metabolic Syndrome, such as lipid abnormalities, the overall strength of evidence is limited. Current dietary guidelines often recommend ALA-rich foods as part of a balanced diet, but ALA supplementation as a primary intervention for Metabolic Syndrome is not strongly endorsed by major medical organizations at this time.

More about Alpha-Linolenic Acid
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by Alpha-Linolenic Acid

Products containing Alpha-Linolenic Acid